-
公开(公告)号:HK1096088A1
公开(公告)日:2007-05-25
申请号:HK07102667
申请日:2004-09-10
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , A61K20060101 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D20060101 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
Abstract: Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
-
公开(公告)号:ES2272742T3
公开(公告)日:2007-05-01
申请号:ES02750339
申请日:2002-07-25
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , C07D521/00 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4035 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04
Abstract: Un compuesto de fórmula (I): en la que: A se selecciona del grupo constituido por arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, arilalquilo, y alquilheteroarilo. W se selecciona del grupo constituido por arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido. E se selecciona del grupo constituido por H, alquilo C1-C8, polihaloalquilo, cicloalquilo C3-8, arilo, arilalquilo, arilo sustituido, heteroarilo, y heteroarilo sustituido. D es en la que: n es un número entero de 0-4, Q es independientemente C o N, en la que cuando Q es un átomo de carbono anular, cada átomo de carbono anular está sustituido independientemente por X, en la que X es en cada caso un miembro seleccionado independientemente del grupo constituido por: H, halógeno, polihaloalquilo, ¿OR3, ¿SR3, ¿CN, ¿NO2, ¿SO2R3, alquilo C1-10, cicloalquilo C3-8, arilo, arilo sustituido por 1-4 grupos R3, amino, aminoalquilo C1-8, acilamino C1-3, acilamino C1-3-alquilo C1-8, alquilamino C1-6, alquilamino-C1-6-alquiloC1-8, dialquilamino C1-6, dialquilamino-C1-6-alquilo C1- 8, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxialquilo C1-6, alcoxi-C1-3-carbonilo, alcoxi-C1-3-carbonilalquilo C1-6, carboxialquiloxi C1-6, hidroxi, hidroxialquilo C1- 6, y un sistema anular heterocíclico de 5 a 10 miembros fusionado o no fusionado, aromático o no aromático, que tiene de 1 a 4 heteroátomos seleccionados independientemente entre N, O, y S, con la condición de que los átomos de carbono y nitrógeno, cuando estén presentes en el sistema anular heterocíclico, estén sin sustituir, mono- o di-sustituidos independientemente con 0-2 grupos R4, en la que R3 y R4 cada uno se selecciona independientemente del grupo constituido por: H, halógeno, ¿CN, ¿NO2, alquilo C1-10, cicloalquilo C3-8, arilo, amino, aminoalquilo C1-8, acilamino C1-3, acilamino C1-3-alquilo C1-8, alquilamino C1-6, alquilamino-C1-6-alquilo C1-8, dialquilamino C1-6, dialquilamino-C1-6-alquilo C1- 8, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxialquilo C1-6, alcoxi-C1-3-carbonilo, alcoxi-C1-3-carbonilalquilo C1-6, carboxialquiloxi C1-6, hidroxi, hidroxialquilo C1- 6, -tio y tio-alquilo C1-6; e Y se selecciona del grupo constituido por O, S, N¿OR5, y NR5, en las que R5 se selecciona del grupo constituido por: H, alquilo C1-10, cicloalquilo C3-8, NR2, y CN; o sales farmacéuticamente aceptables.
-
公开(公告)号:DE60214730D1
公开(公告)日:2006-10-26
申请号:DE60214730
申请日:2002-07-25
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK M , MARLOWE K , KANE-MAGUIRE A
IPC: C07D239/96 , C07D521/00 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4035 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04
Abstract: Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
-
公开(公告)号:AU2004278030A1
公开(公告)日:2005-04-14
申请号:AU2004278030
申请日:2004-09-29
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , ZHANG XIAOMING , BAUER SHAWN M , HUANG WOLIN , PANDEY ANJALI , JIA ZHAOZHONG J
IPC: C07D409/12 , A61K20060101 , A61K31/517 , A61P7/02 , C07D409/14
Abstract: 2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C 1-6 alkyl; R 1 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl and C 3-5 cycloalkyl-alkyl; R 2 is a member selected from the group consisting of H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, cyano and -C(O)R 2a , wherein R 2a is a member selected from the group consisting of C 1-6 alkoxy and (C 1-6 alkyl) 0-2 amino; L is a 1 to 3 carbon linking group selected from the group consisting of -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 -, -CH 2 CH(CH 3 )- and -CH 2 CH 2 CH 2 -; L 1 is a linking group selected from the group consisting of a bond and -CH 2 -; L 2 is a linking group selected from the group consisting of a bond, -NH- and -CH 2 -; and Ar 1 is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine; are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
-
公开(公告)号:HK1064099A1
公开(公告)日:2005-01-21
申请号:HK04106901
申请日:2004-09-10
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D20060101 , C07D239/96 , A61K20060101 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
Abstract: Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
-
公开(公告)号:CA2728893C
公开(公告)日:2017-03-14
申请号:CA2728893
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: VENKATARAMANI CHANDRASEKAR , HUANG WOLIN , MEHROTRA MUKUND , SONG YONGHONG , XU QING , BAUER SHAWN M , PANDEY ANJALI , KANE BRIAN , JIA ZHAOZHONG J , ROSE JACK W
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods ofinhibilion the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimune disease and cell proliferative disorder. Formula (I) Y1 is selected from the group consisting of: (a) and (b); Z is O or S; D1 is selected from the group consisting of: (a) phenyl substituted with a group, R5 (b) naphthyl (c) C3-8cycloalkyl (d) heteroaryl (e) heterocyclyl
-
公开(公告)号:HRP20161310T1
公开(公告)日:2016-12-02
申请号:HRP20161310
申请日:2016-10-11
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
-
公开(公告)号:ES2546502T3
公开(公告)日:2015-09-24
申请号:ES09742982
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: JIA ZHAOZHONG J , VENKATARAMANI CHANDRASEKAR , HUANG WOLIN , MEHROTRA MUKUND , SONG YONGHONG , XU QING , BAUER SHAWN M , PANDEY ANJALI , KANE BRIAN , ROSE JACK W
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: Un compuesto que tiene la fórmula (I):**Fórmula** o uno de sus tautómeros o sales farmacéuticamente aceptables, en donde: D1 es fenilo sustituido con heteroarilo; cada E1 está seleccionado de modo independiente del grupo que consiste en alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-8, alquil C1-8-tio, aminocarbonilo, alcoxi C1-8-carbonil-alquileno C1-8, alcoxi C1-8-carbonil C1-8alcoxi C1-8, alcoxi C1-8-carbonilamino, oxo, halo, ciano, haloalquilo C1-8, haloalcoxi C1-8, aminosulfonilo, heteroarilsulfinilo; amino, hidroxilo, arilalquileno C1-8, fenilo, aminoalquilo C1-8, aminocicloalquilo C3-8, heterociclilo, heteroarilo, acilo C1-8, alquil C1-8 sulfonilo, acilamino y heterociclilalquileno C1-8; el subíndice n es 0, 1, 2, 3 ó 4; el resto:**Fórmula** es bien: (a)**Fórmula** y donde X e Y están seleccionados independientemente del grupo que consiste en: CH2, NH, NCOOH3 y S; (b) seleccionado del grupo que consiste en:**Fórmula** y donde cada R8a y R8b es independientemente H, hidroxilo, halo o si están en carbonos adyacentes, pueden combinarse con los átomos a los que están unidos para formar un anillo de benceno fusionado; y cada R9a y R9b es independientemente H, hidroxilo, halo o si están en carbonos adyacentes, pueden combinarse con los átomos a los que están unidos para formar un anillo de benceno fusionado; y la línea ondulada indica el punto de unión al resto de la molécula; o**Fórmula** (c) donde cada R8a y R8b es independientemente H o pueden combinarse con los átomos a los que están unidos para formar un anillo de benceno fusionado; y la línea ondulada indica el punto de unión al resto de la molécula; y "cicloalquilo" se refiere a un grupo hidrocarbonado mono o policíclico alifático, que puede formar un anillo con puente o un anillo espiro, y que puede tener uno o más enlaces dobles o triples.
-
公开(公告)号:AU2009244897B2
公开(公告)日:2014-11-13
申请号:AU2009244897
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: MEHROTRA MUKUND , HUANG WOLIN , SONG YONGHONG , JIA ZHAOZHONG J , XU QING , VENKATARAMANI CHANDRASEKAR , BAUER SHAWN M , PANDEY ANJALI , ROSE JACK , KANE BRIAN
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods ofinhibilion the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder. Formula (I) Y
-
公开(公告)号:EA019973B1
公开(公告)日:2014-07-30
申请号:EA201001618
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: JIA ZHAOZHONG J , VENKATARAMANI CHANDRASEKAR , HUANG WOLIN , MEHROTRA MUKUND , SONG YONGHONG , XU QING , BAUER SHAWN M , PANDEY ANJALI , KANE BRIAN , ROSE JACK W
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: Изобретениенаправленонасоединенияформул I-V иихтаутомерыилиихфармацевтическиприемлемыесоли, сложныеэфирыи пролекарства, которыеявляютсяингибиторамикиназы Syk. Изобретениетакженаправленонапромежуточныесоединения, используемыедляполучениятакихсоединений, получениетакихсоединений, фармацевтическиекомпозиции, содержащиетакиесоединения, способыингибированияактивности Syk-киназы, способыингибированияагрегациитромбоцитов, испособыпредотвращенияилилечениярядасостояний, опосредованных, поменьшеймере, частичноактивностью Syk-киназы, такойкакнежелательныйтромбозози неходжкинскаялимфома.
-
-
-
-
-
-
-
-
-